Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 376 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is R  [Clear All Filters]
2026
Hunt DM, Pisco JPedro, Rodgers A, de Chiara C, Zaveri A, Pacholarz KL, Evangelopoulos D, Garza-Garcia A, Ehrt S, Schnappinger D et al..  2026.  Activation of L-histidine biosynthesis as a new antibiotic strategy against Mycobacterium tuberculosis.. Nat Commun. 17(1)
Seshadri C, Flynn JAL, Maiello P, Schnappinger D, Wilkinson RJ, Gordon SB, Mwandumba HC, Jambo KC, Hoft DF, Rubin EJ et al..  2026.  Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials.. Lancet Microbe. :101278.
Liu Q, Engelhart CA, Wallach JB, Ge P, Wong T-Y, Orimoloye MO, Rodriguez S, Jayasinghe YP, Ronning DR, Dartois V et al..  2026.  Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.. J Med Chem.
Liu Q, Engelhart CA, Wallach JB, Ge P, Wong T-Y, Orimoloye MO, Rodriguez S, Jayasinghe YP, Ronning DR, Dartois V et al..  2026.  Design, Synthesis and Biological Evaluation of Potent Piperazine-Based BioA Inhibitors Targeting Biotin Biosynthesis in Mycobacterium tuberculosis.. J Med Chem.
Warrier T, Martinez-Hoyos M, de Francisco EPorras, Lenaerts AJ, Gruppo V, Robertson GT, Li K, Aubé J, Bonnet I, Jiang X et al..  2026.  Diaryl-Aminoindazole with Extensive In Vitro Mycobactericidal Activity Dependent on Exposure to Reactive Nitrogen Species.. ACS Infect Dis.
Naylor C, Prosser G, Bayliss T, Berle LF, Wallach JB, Kim H, Olvera RAguilera, Thompson S, Ioerger TR, Simpson L et al..  2026.  Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against Mycobacterium tuberculosis.. ACS Infect Dis.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Moses A, Zhang A, Todorovic M, Ramakrishna R, Facciani M, Eagleman DM, Sever R, Eyre HA, Bhamla S, Moore JP et al..  2026.  Modern science outreach: A guide for scientists.. Cell. 189(17):5174-5181.
Moses A, Zhang A, Todorovic M, Ramakrishna R, Facciani M, Eagleman DM, Sever R, Eyre HA, Bhamla S, Moore JP et al..  2026.  Modern science outreach: A guide for scientists.. Cell. 189(17):5174-5181.
Moses A, Zhang A, Todorovic M, Ramakrishna R, Facciani M, Eagleman DM, Sever R, Eyre HA, Bhamla S, Moore JP et al..  2026.  Modern science outreach: A guide for scientists.. Cell. 189(17):5174-5181.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Fries F, Herrmann J, Dal Molin M, Wormser Y, Risch T, Gao Y, Prosser G, Gubellini F, Mechaly A, Wallach JB et al..  2026.  The Natural Product Corramycin Acts as a DNA Gyrase Poison and Overcomes Fluoroquinolone Resistance in Mycobacterium tuberculosis.. Adv Sci (Weinh). :e76832.
Klevorn T, Brown C, Hardy CD, Cuthbert BJ, Spencer A, Jinich A, Chan L, Angala SK, Manzer J, Mendoza J et al..  2026.  A periplasmic protein complex mediates arabinofuranosyltransferase activity and intrinsic drug resistance in Mycobacterium tuberculosis.. Sci Adv. 12(14):eaec5100.
Liu Y, Ruecker N, Faulkner V, Rachineni K, Al-Saffar N, Oskoui E, Garcia LZarate, Rowley JEmma, Teixeira PVillacampa, Costa TRD et al..  2026.  Rv3400 is a phosphoglucomutase required for trehalose metabolism in Mycobacterium tuberculosis.. J Bacteriol. :e0034326.
Liu Y, Ruecker N, Faulkner V, Rachineni K, Al-Saffar N, Oskoui E, Garcia LZarate, Rowley JEmma, Teixeira PVillacampa, Costa TRD et al..  2026.  Rv3400 is a phosphoglucomutase required for trehalose metabolism in Mycobacterium tuberculosis.. J Bacteriol. :e0034326.
Liu Y, Ruecker N, Faulkner V, Rachineni K, Al-Saffar N, Oskoui E, Garcia LZarate, Rowley JEmma, Teixeira PVillacampa, Costa TRD et al..  2026.  Rv3400 is a phosphoglucomutase required for trehalose metabolism in Mycobacterium tuberculosis.. J Bacteriol. :e0034326.
Liu Y, Ruecker N, Faulkner V, Rachineni K, Al-Saffar N, Oskoui E, Garcia LZarate, Rowley JEmma, Teixeira PVillacampa, Costa TRD et al..  2026.  Rv3400 is a phosphoglucomutase required for trehalose metabolism in Mycobacterium tuberculosis.. J Bacteriol. :e0034326.
Courbon GM, Makarov V, Cole ST, Schnapinger D, Ehrt S, Rubinstein JL.  2026.  Structural basis for EtfD-mediated coupling of β-oxidation and the respiratory chain in mycobacteria.. EMBO J. 45(8):2785-2807.
Theriault ME, Wong AI, DeJesus MA, Pisu D, Lee BNae Rin, Kirukubar G, Li S, Wallach JB, Schnappinger D, Lê-Bury G et al..  2026.  Utilization of a CRISPRi-based ex vivo challenge model to reveal temporally dependent gene essentiality in intracellular Mycobacterium tuberculosis.. mBio. :e0061026.
Theriault ME, Wong AI, DeJesus MA, Pisu D, Lee BNae Rin, Kirukubar G, Li S, Wallach JB, Schnappinger D, Lê-Bury G et al..  2026.  Utilization of a CRISPRi-based ex vivo challenge model to reveal temporally dependent gene essentiality in intracellular Mycobacterium tuberculosis.. mBio. :e0061026.